User profiles for Aashil A. Batavia
Aashil A. BataviaNovartis, SIB Verified email at novartis.com Cited by 177 |
Clear cell renal cell carcinoma with wild‐type von Hippel‐Lindau gene: a non‐existent or new tumour entity?
AA Batavia, P Schraml, H Moch - Histopathology, 2019 - Wiley Online Library
The current World Health Organisation ( WHO ) classification of renal tumours is based on
characteristic histological features or specific molecular alterations. von Hippel‐Lindau ( VHL ) …
characteristic histological features or specific molecular alterations. von Hippel‐Lindau ( VHL ) …
[HTML][HTML] Biallelic ELOC-inactivated renal cell carcinoma: molecular features supporting classification as a distinct entity
AA Batavia, D Rutishauser, B Sobottka, P Schraml… - Modern Pathology, 2023 - Elsevier
Approximately 70% of clear cell renal cell carcinoma (ccRCC) is characterized by the biallelic
inactivation of von Hippel-Lindau (VHL) on chromosome 3p. ELOC-mutated (Elongin C-…
inactivation of von Hippel-Lindau (VHL) on chromosome 3p. ELOC-mutated (Elongin C-…
[HTML][HTML] The vascular gene Apold1 is dispensable for normal development but controls angiogenesis under pathological conditions
The molecular mechanisms of angiogenesis have been intensely studied, but many genes
that control endothelial behavior and fate still need to be described. Here, we characterize …
that control endothelial behavior and fate still need to be described. Here, we characterize …
[HTML][HTML] Classic chromophobe renal cell carcinoma incur a larger number of chromosomal losses than seen in the eosinophilic subtype
Chromophobe renal cell carcinoma (chRCC) is a renal tumor subtype with a good prognosis,
characterized by multiple chromosomal copy number variations (CNV). The World Health …
characterized by multiple chromosomal copy number variations (CNV). The World Health …
[HTML][HTML] Loss of CDKN1A mRNA and protein expression are independent predictors of poor outcome in chromophobe renal cell carcinoma patients
Chromophobe renal cell carcinoma (chRCC) patients have good prognosis. Only 5%–10%
patients die of metastatic disease after tumorectomy, but tumor progression cannot be …
patients die of metastatic disease after tumorectomy, but tumor progression cannot be …
Within-patient genetic diversity of SARS-CoV-2
SARS-CoV-2, the virus responsible for the current COVID-19 pandemic, is evolving into
different genetic variants by accumulating mutations as it spreads globally. In addition to this …
different genetic variants by accumulating mutations as it spreads globally. In addition to this …
[HTML][HTML] Impact of differing methodologies for serum miRNA-371a-3p assessment in stage I testicular germ cell cancer recurrence
Current evidence shows that serum miR-371a-3p can identify disease recurrence in testicular
germ cell tumour (TGCT) patients and correlates with tumour load. Despite convincing …
germ cell tumour (TGCT) patients and correlates with tumour load. Despite convincing …
[HTML][HTML] Spatial distribution of private gene mutations in clear cell renal cell carcinoma
Simple Summary Tumours consist of multiple groups of similar cells resulting from differing
evolutionary trajectories, ie, subclones. These subclones are prevalent in clear cell renal cell …
evolutionary trajectories, ie, subclones. These subclones are prevalent in clear cell renal cell …
[HTML][HTML] Next Generation Sequencing of Reactive Stroma and Residual Breast Cancer Cells in Tumor Bed after Neoadjuvant Chemotherapy
…, A Christiansen, M Lukamowicz-Rajska, AA Batavia… - Cancers, 2022 - mdpi.com
Simple Summary Primary systemic or neoadjuvant chemotherapy of breast cancer has become
a standard therapy option in locally advanced or triple negative or Her2 positive breast …
a standard therapy option in locally advanced or triple negative or Her2 positive breast …
[HTML][HTML] Prognostic immune cell profiling of malignant pleural effusion patients by computerized immunohistochemical and transcriptional analysis
Malignant pleural effusion (MPE) is a severe condition of advanced tumors without effective
therapy. We used digitalized immunohistochemical and transcriptional approaches to …
therapy. We used digitalized immunohistochemical and transcriptional approaches to …